Predictors of completion of a hepatitis B vaccination schedule in attendees at a primary health care centre

Sexual Health

Volumn 4, Issue 1, 2007, Pages 27-30

  Macdonald, Virginia ^a   Dore, Gregory J ^b   Amin, Janaki ^b   Van Beek, Ingrid ^a  

^a South Eastern Sydney and Illawarra Area Health Service   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT HEPATITIS B VACCINE;

ADULT; ARTICLE; AUSTRALIA; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG USE; FEMALE; HEALTH CENTER; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PREDICTION; PRIMARY HEALTH CARE; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; VACCINATION; VIRUS IMMUNITY;

ADOLESCENT; ADULT; ATTITUDE TO HEALTH; FEMALE; HEALTH CARE SURVEYS; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION PROGRAMS; MALE; NEW SOUTH WALES; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT COMPLIANCE; PRIMARY HEALTH CARE; VACCINATION;

EID: 33847217312     PISSN: 14485028     EISSN: None     Source Type: Journal    
DOI: 10.1071/SH06008     Document Type: Article

References (21)

1. Williams A. Reduction in hepatitis B related burden of disease - measuring the success of universal immunisation programs. Commun Dis Intell 2002; 26(3): 458-60.
2. Kao J-H, Chen D-S. Global control of hepatitis B virus infection. Lancet Infect Dis 2002; 2: 395-403. doi: 10.1016/S1473-3099(02)00315-8
3. National Centre in HIV Epidemiology and Clinical Research (NCHECR). HIV/AIDS, viral hepatitis and sexually transmissible infection in Australia: Annual Surveillance Report 2004. Sydney: NCHECR; 2004.
4. O'Sullivan BG, Gidding HF, Law M, Kaldor JM, Gilbert GL, Dore GJ. Estimates of chronic hepatitisBvirus infection in Australia, 2000. Aust NZ J Public Health 2004; 28: 212-6.
5. van Steenbergen JE. Results of an enhanced-outreach programme of hepatitis B vaccination in the Netherlands (1998-2000) among men who have sex with men, hard drug users, sex workers and heterosexual persons with multiple partners. J Hepatol 2002; 37: 507-13. doi: 10.1016/S0168-8278(02)00213-1
6. Minuk GY, Sun DF, Greenberg R, Zhang M, Hawkins K, Uhanova J, et al. Occult hepatitis B virus infection in a North American adult hemodialysis patient population. Hepatology 2004; 40(5): 1072-7. doi: 10.1002/hep.20435
7. Anderson B, Bodsworth NJ, Rohrsheim RA, Donovan BJ. Hepatitis B virus infection and vaccination status of high risk people in Sydney: 1982 and 1991. Med J Aust 1994; 161: 368-71.
8. Crofts N, Aitken CK. Incidence of bloodborne virus infection and risk behaviours in a cohort of injecting drug users in Victoria, 1990-1995. Med J Aust 1997; 167: 17-20.
9. Kaldor JM, Plant AJ, Thompson SC, Longbottom H, Rowbottom J. The incidence of hepatitis B infection in Australia: an epidemiological review. Med J Aust 1996; 165: 322-6.
10. van Beek I, Buckley R, Stewart M, MacDonald M, Kaldor. Risk factors for hepatitis C virus infection among injecting drug users in Sydney. Genitourin Med 1994; 70(5): 321-4.
11. Sterling RK, Sulkowski MS. Hepatitis C virus in the setting of HIV or hepatitis B coinfection. Semin Liver Dis 2004; 24(Suppl. 2): 61-8. doi: 10.1055/s-2004-832930
12. Maher L, Chant K, JalaludinB, Sargent P. Risk behaviours and antibody hepatitis B and C prevalence among injecting drug users in southwestern Sydney, Australia. J Gastroenterol Hepatol 2004; 19(10): 1114-20. doi: 10.1111/j.1440-1746.2004.03438.x
13. Day C, White B, Ross J, Dolan K. Poor knowledge and low coverage of hepatitis B vaccination among injecting drug users in Sydney. Aust NZ J Public Health 2003; 27(5): 558.
14. Saltoglu N, Inal AS, Tasova Y, Kandemir O. Comparison of the accelerated and classic vaccination schedules against Hepatitis B: three-week Hepatitis B vaccination schedule provides immediate and protective immunity. Ann Clin Microbiol Antimicrob 2003; 2(1): 10-4. doi: 10.1186/1476-0711-2-10
15. Marchout B, Picot N, Chavanet P, Auvergnat JC, Armengaud M, Devilliers P, et al. Three-week hepatitis B vaccination provides protective immunity. Vaccine 1993; 11(14): 1383-5. doi: 10.1016/0264-410X(93)90165-T
16. Rogers N, Lubman DI. An accelerated schedule for young drug users. Aust NZ J Public Health 2005; 29(4): 305-7.
17. Harries AD, Clark M, Beeching NJ, Lavelle J, Mutton KJ. Early anti-HBs antibody response to accelerated and to conventional hepatitis B vaccination regimens in healthy persons. J Infect 1991; 23(3): 251-4. doi: 10.1016/0163-4453(91)92792-4
18. McGregor J, Marks PJ, Hayward A, Bell Y, Slack RC. Factors influencing hepatitis B vaccine uptake in injecting drug users. J Public Health Med 2003; 25(2): 165-70. doi: 10.1093/pubmed/fdg035
19. Richter A, Anton SE, Koch P, Dennett SL. The impact of reducing dose frequency on health outcomes. Clin Ther 2003; 25(8): 2307-35. doi: 10.1016/S0149-2918(03)80222-9
20. ul-Haq N, Hasnain SS, Umar M, Abbas Z, Valenzuela-Silva C, Lopez-Saura P. Immunogencity of 10 and 20 microgram hepatitis B vaccine in a two-dose schedule. Vaccine 2003; 21(23): 3179-85. doi: 10.1016/S0264-410X(03) 00232-9
21. Seal KH, Kral AH, Lorvick J, McNees A, Gee L, Edlin BR. A randomised controlled trial of monetary incentives vs. outreach to enhance adherence to the hepatitis B vaccine series among injection drug users. Drug Alcohol Depend 2003; 71: 127-31. doi: 10.1016/S0376-8716(03)00074-7